Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1–3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3–altered Advanced/Metastatic Urothelial Carcinoma

Yung Lyou, Petros Grivas, Jonathan E. Rosenberg, Jean Hoffman-Censits, David I. Quinn, Daniel P. Petrylak, Matthew Galsky, Ulka Vaishampayan, Ugo De Giorgi, Sumati Gupta, Howard Burris, Jessica Rearden, Ai Li, Hao Wang, Maribel Reyes, Susan Moran, Siamak Daneshmand, Dean Bajorin, Sumanta K. Pal

Research output: Contribution to journalArticlepeer-review

Abstract

Targeted therapy is a new paradigm in treating bladder cancer. In a study using infigratinib, a drug that targets mutations in a gene called fibroblast growth factor receptor 3 (FGFR3), we found that elevated levels of phosphorous were associated with greater clinical benefit. In the future, these data may help inform treatment strategies.

Original languageEnglish (US)
Pages (from-to)916-924
Number of pages9
JournalEuropean Urology
Volume78
Issue number6
DOIs
StatePublished - Dec 2020

Keywords

  • Biomarker
  • Fibroblast growth factor receptor
  • Hyperphosphatemia
  • Infigratinib
  • Pharmacodynamics
  • Pharmacokinetics
  • Response rate
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1–3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3–altered Advanced/Metastatic Urothelial Carcinoma'. Together they form a unique fingerprint.

Cite this